The creation and study of ARL13A Activators would begin with a comprehensive structural assessment of the protein. Techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy might be employed to elucidate the three-dimensional structure of ARL13A, particularly focusing on the GTP-binding domain. This domain is where GTPase activity occurs, and therefore, it would be the primary target for activation. Activators might be designed to bind to allosteric sites that can influence the conformation of the GTP-binding domain, thereby increasing the efficiency of GTP binding or hydrolysis. Alternatively, activators could interact directly with the active site to stabilize the transition state of the GTP hydrolysis reaction, enhancing the protein's natural activity.
Following the identification of potential activator molecules, a series of biochemical assays would be crucial to evaluate their impact on ARL13A activity. GTPase assays could be implemented to quantify the GTP hydrolysis rate in the presence of these compounds, providing a direct measure of activation. In parallel, binding studies could be performed to determine the affinity of these activators for ARL13A, which would involve techniques such as isothermal titration calorimetry or fluorescence-based thermal shift assays. These studies would facilitate an understanding of the interaction between ARL13A and the activators at a molecular level. Iterative chemical synthesis and structure-activity relationship (SAR) analysis would be employed to refine the activator molecules, optimizing their potency and selectivity for ARL13A. The use of such activators would advance the understanding of the biological function of ARL13A and contribute to the broader knowledge of the ARL family of GTPases and their roles in cellular physiology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
May increase cAMP levels, leading to activation of PKA which can phosphorylate and regulate GTPases. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Activator of Protein Kinase C (PKC) which may phosphorylate and regulate GTPases. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits GSK-3β, potentially affecting Wnt signaling and GTPase function. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Influences gene expression and might modulate GTPase activity during cellular differentiation. | ||||||
Manganese(II) chloride beads | 7773-01-5 | sc-252989 sc-252989A | 100 g 500 g | $19.00 $30.00 | ||
Required as a cofactor for many enzymes, could affect GTPase activation state. | ||||||
Sodium nitroprusside dihydrate | 13755-38-9 | sc-203395 sc-203395A sc-203395B | 1 g 5 g 100 g | $42.00 $83.00 $155.00 | 7 | |
NO can modulate protein function and signaling pathways involving GTPases. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
Increases intracellular Ca2+, which can activate calmodulin and influence GTPases. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Hsp90 inhibitor, could affect client proteins including GTPases. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
Inhibits HMG-CoA reductase; could affect prenylation and therefore the localization and function of GTPases. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Could prevent the degradation of GTPases, potentially increasing their activity. | ||||||